Amgen appeal tests antitrust reach over pending patent rights
Review by the US Court of Appeals for the Fourth Circuit of Amgen’s Enbrel patent strategy could clarify that acquisitions of rights to pending patent applications receive no categorical exemption from...To view the full article, register now.
Already a subscriber? Click here to view full article